Rabbit Polyclonal RAD51C Antibody

+ +

•  

   
     Western blot analysis of OLFML2A expression in HepG2, A549 whole cell lysates.    

•  

   
     Immunofluorescent analysis of RAD51C staining in HeLa cells. Formalin-fixed cells were permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with the primary antibody in 3% BSA-PBS and incubated overnight at 4 C in a hidified chamber. Cells were washed with PBST and incubated with a DyLight 594-conjugated secondary antibody (red) in PBS at room temperature in the dark.    

•  

   
     Immunohistochemical analysis of RAD51C staining in human breast cancer formalin fixed paraffin embedded tissue section. The section was then incubated with the antibody at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.    

The RAD51C antibody is a crucial tool for studying the RAD51C protein, a key component of the homologous recombination repair (HRR) pathway responsible for repairing DNA double-strand breaks (DSBs). RAD51C is a member of the RAD51 paralog family, which also includes RAD51B, RAD51D, XRCC2. and XRCC3. It forms stable complexes with other paralogs to facilitate the assembly and stabilization of RAD51 nucleoprotein filaments, essential for homology search and strand pairing during HRR. RAD51C is also linked to the Fanconi anemia (FA) pathway, contributing to interstrand crosslink repair.

Mutations or dysregulation of RAD51C are associated with cancer predisposition, particularly hereditary breast and ovarian cancers (HBOC), often in patients without BRCA1/2 mutations. Loss-of-function variants in RAD51C are classified as moderate-risk factors for these cancers, with implications for clinical management and genetic counseling. Additionally, reduced RAD51C expression correlates with genomic instability, poor prognosis, and chemoresistance in various malignancies.

The RAD51C antibody enables detection and localization of the protein in cells or tissues via techniques like Western blotting, immunofluorescence (IF), or immunohistochemistry (IHC). Researchers use it to investigate RAD51C expression patterns, subcellular distribution, and interactions with repair machinery components. Its utility extends to studying HRR deficiency as a biomarker for predicting responses to PARP inhibitors or platinum-based therapies in cancer. Validated antibodies are critical for ensuring specificity, given the structural similarities among RAD51 paralogs.